Latest Hospitality News

Eden Innovations Ltd reports a striking 158% increase in US OptiBlend® sales for Q2 FY25, alongside expanding international traction for its EdenCrete® products and strategic property sales aimed at debt reduction.

Genetic Signatures reported a robust 190% increase in quarterly sales to $3.8 million, driven by strong respiratory testing demand in Australia and strategic UK deployments. Despite longer US sales cycles, the company maintains a solid $40.8 million cash position and advances R&D on its 3base® platform.

Optiscan Imaging Ltd reported a productive December quarter, marked by key product developments, strategic partnerships, and a stronger cash position, setting the stage for growth in medical and veterinary imaging markets.

Imugene Limited reports durable patient responses in multiple cancer immunotherapy trials and strengthens its financial position with a $46 million convertible note deal and a substantial R&D tax refund.

Ramsay Health Care announces key leadership departures and a strategic realignment aimed at strengthening its core Australian hospital business and accelerating transformation under CEO Natalie Davis.

PainChek Ltd reports robust growth with 100,000 contracted licences globally and positive FDA clearance progress, alongside a promising launch of its Infant App targeting a vast new market.

TrivarX has solidified its regulatory strategy for the pivotal MEB-001 trial with the FDA and unveiled a new algorithm that expands its mental health screening reach beyond sleep clinics.

Medical Developments International has posted a robust improvement in operating cash flow and revenue for Q2 FY25, driven by higher demand and pricing for its flagship product Penthrox across Australia and Europe.

Echo IQ Limited has secured FDA clearance for its EchoSolv AS technology and appointed a US-based CEO, marking a pivotal shift towards commercialisation in the American healthcare market.

Tryptamine Therapeutics has reported successful Phase 1b results for its IV-infused psilocin candidate TRP-8803 and promising interim data for oral psilocybin TRP-8802 in IBS treatment, while securing $6 million in new funding to accelerate clinical development.

Argenica Therapeutics has received a positive safety review from its independent DSMB for the Phase 2 trial of ARG-007 in acute ischaemic stroke patients, with dosing now 86% complete and full recruitment expected by early Q2 2025.

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.